Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine. CL...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Infect Dis
Main Authors: Taiwo, Babafemi O, Marconi, Vincent C, Berzins, Baiba, Moser, Carlee B, Nyaku, Amesika N, Fichtenbaum, Carl J, Benson, Constance A, Wilkin, Timothy, Koletar, Susan L, Colasanti, Jonathan, Acosta, Edward P, Li, Jonathan Z, Sax, Paul E
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961309/
https://ncbi.nlm.nih.gov/pubmed/29293895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cix1131
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares